MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Seroquel in Bipolar Depression Versus SSRI

Phase 3
Completed
Conditions
Bipolar Disorder
Bipolar Depression
Depression
First Posted Date
2005-07-14
Last Posted Date
2013-01-04
Lead Sponsor
AstraZeneca
Target Recruit Count
676
Registration Number
NCT00119652
Locations
🇹🇷

Research Site, Manisa, Turkey

Serotonin and the Upper Airway in Obstructive Sleep Apnea

Phase 4
Completed
Conditions
Obstructive Sleep Apnea
First Posted Date
2004-12-31
Last Posted Date
2013-09-17
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00100464
Locations
🇺🇸

Malcolm Randall VA Medical Center, Gainesville, Florida, United States

Study of Antidepressants in Parkinson's Disease

Phase 3
Completed
Conditions
Parkinson Disease
Depression
Interventions
First Posted Date
2004-06-29
Last Posted Date
2013-01-04
Lead Sponsor
University of Rochester
Target Recruit Count
115
Registration Number
NCT00086190
Locations
🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

University of Maryland, Baltimore, Maryland, United States

and more 15 locations

Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder

Phase 3
Completed
Conditions
Social Anxiety Disorder
Interventions
Behavioral: Cognitive behavioral therapy (CBT)
First Posted Date
2003-12-22
Last Posted Date
2017-06-14
Lead Sponsor
Temple University
Target Recruit Count
150
Registration Number
NCT00074802
Locations
🇺🇸

Adult Anxiety Clinic of Temple University, Philadelphia, Pennsylvania, United States

🇺🇸

New York State Psychiatric Institute Anxiety Disorders Clinic, New York, New York, United States

Depression Study In Elderly Patients

Phase 3
Completed
Conditions
Depressive Disorder, Major
Major Depressive Disorder (MDD)
First Posted Date
2003-08-21
Last Posted Date
2016-09-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
560
Registration Number
NCT00067444
Locations
🇺🇸

GSK Investigational Site, Salt Lake City, Utah, United States

Treatment of Depression in Parkinson's Disease Trial

Phase 2
Completed
Conditions
Parkinson Disease
Depression
Interventions
First Posted Date
2003-06-13
Last Posted Date
2015-11-24
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
52
Registration Number
NCT00062738
Locations
🇺🇸

Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Major Depressive Disorder Study In Adults

Phase 4
Completed
Conditions
Major Depressive Disorder
First Posted Date
2002-11-19
Last Posted Date
2017-09-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
646
Registration Number
NCT00049972
Locations
🇺🇸

GSK Clinical Trial Call Center, Kirkland, Washington, United States

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Phase 3
Completed
Conditions
Major Depressive Disorder
First Posted Date
2002-11-05
Last Posted Date
2017-05-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
600
Registration Number
NCT00048607

A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder

Phase 2
Completed
Conditions
Depressive Disorder, Major
First Posted Date
2002-10-30
Last Posted Date
2017-10-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
372
Registration Number
NCT00048204

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Phase 3
Completed
Conditions
Major Depressive Disorder
First Posted Date
2002-05-03
Last Posted Date
2017-04-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
468
Registration Number
NCT00035009
© Copyright 2025. All Rights Reserved by MedPath